Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Saudi Med J ; 45(4): 437-441, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38657980

ABSTRACT

OBJECTIVES: To investigate differences in the incidence of enteropathy or intestinal malabsorption in patients taking angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitor (ACEI), calcium channel blocker (CCB), and beta blockers (BBs) at a single center in Korea. METHODS: In this retrospective study, we utilized data from the Yangsan electronic medical records to identify 129,169 patients. These individuals were prescribed olmesartan, other ARBs, ACEI, CCB, and BBs between November 2008 and February 2021. RESULTS: Of the 44,775 patients, 51 (0.11%) were observed to have enteropathy or intestinal malabsorption. Compared with the ACEI group, the adjusted odds ratios (ORs) for enteropathy and intestinal malabsorption were OR=1.313 (95% confidence interval [CI]: [0.188-6.798], p=0.893) for olmesartan, OR=0.915 (95% CI: [0.525-1.595], p=0.754) for the other ARBs, OR=0.928 (95% CI: [0.200-4.307]; p=0.924) for the CCB, and OR=0.663 (95% CI: [0.151-2.906]; p=0.586) for the BBs group. These findings were adjusted for factors such as age, gender, duration of antihypertensive medication, and comorbidities. CONCLUSION: In a retrospective cohort study of patients on antihypertensive medications, no significant difference was found in the incidence of enteropathy or intestinal malabsorption when ACEI was compared to olmesartan, other ARBs, CCB, and BBs.


Subject(s)
Angiotensin Receptor Antagonists , Angiotensin-Converting Enzyme Inhibitors , Antihypertensive Agents , Calcium Channel Blockers , Malabsorption Syndromes , Humans , Retrospective Studies , Male , Female , Middle Aged , Malabsorption Syndromes/epidemiology , Malabsorption Syndromes/complications , Antihypertensive Agents/therapeutic use , Aged , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Angiotensin Receptor Antagonists/therapeutic use , Angiotensin Receptor Antagonists/adverse effects , Calcium Channel Blockers/therapeutic use , Intestinal Diseases/epidemiology , Adrenergic beta-Antagonists/therapeutic use , Adrenergic beta-Antagonists/adverse effects , Imidazoles/therapeutic use , Imidazoles/adverse effects , Tetrazoles/therapeutic use , Incidence , Adult , Republic of Korea/epidemiology , Cohort Studies , Hypertension/drug therapy , Hypertension/epidemiology
2.
J Public Health (Oxf) ; 45(3): e510-e517, 2023 08 28.
Article in English | MEDLINE | ID: mdl-37122205

ABSTRACT

BACKGROUND: Considering the prolongation of the COVID-19 pandemic, the lack of studies on burnout, particularly in healthcare workers, needs to be addressed. This report aimed to identify the risk factors of burnout by comparing the level of burnout between nurses in general wards and those in COVID-19-dedicated wards in a national university hospital. METHODS: A survey based on the Korean version of Burnout Assessment Tool (BAT-K) was conducted on nurses between 10 January and 31 January 2022. The BAT-K consists of exhaustion, mental distance, cognitive impairment, emotional impairment and secondary symptoms. RESULTS: A total of 165 nurses, including 81 nurses from the COVID-19-dedicated ward, completed the questionnaire. The percentage of general-ward nurses with an emotional impairment score above the clinical cutoff was higher than that of COVID-19 ward nurses. General ward compared to the COVID-19 ward increased the risk of presenting with total-core symptoms. Two factors increased the risk regarding mental distance: short career length and underlying disease. CONCLUSIONS: In contrast to previous studies, the risk of burnout in the COVID-19-ward nurses was lower than that of the general ward nurses. The risk regarding mental distance was correlated with short career length and presence of an underlying disease.


Subject(s)
Burnout, Professional , COVID-19 , Humans , COVID-19/epidemiology , Pandemics , Burnout, Professional/epidemiology , Burnout, Professional/psychology , Health Personnel/psychology , Hospitals, University , Surveys and Questionnaires
3.
Exp Mol Med ; 36(1): 13-22, 2004 Feb 29.
Article in English | MEDLINE | ID: mdl-15031666

ABSTRACT

Rheumatoid arthritis (RA) is a multifactorial autoimmune disease whose etiopathogenesis is not well understood. Although soluble (s) forms of 4-1BB (s4-1BB) and 4-1BB legand (s4-1BBL) have been detected in the sera of RA patients, their significance is not known. We compared the serum levels of s4-1BB and s4-1BBL in RA patients with those in systemic lupus erythematosus (SLE) and Behcet's disease (BD) patients. Serum levels of s4-1BB and s4-1BBL were significantly higher in RA patients compared with healthy controls, SLE or BD patients, and the abundance was correlated with disease severity in patients with RA. The serum levels of s4-1BB in RA patients were inversely corroborated with 4-1BB expression levels on activated T lymphocytes. In addition, there was a correlation between serum levels of s4-1BB and s4-1BBL. The augmented secretion of s4-1BB and s4-1BBL levels into the serum may reflect the clinical symptoms of RA and levels of s4-1BB and s4-1BBL in sera at the time of diagnosis may be indicative of the severity and outcome of RA.


Subject(s)
Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/pathology , Receptors, Nerve Growth Factor/blood , Receptors, Tumor Necrosis Factor/blood , Tumor Necrosis Factor-alpha/metabolism , 4-1BB Ligand , Adult , Aged , Antigens, CD/metabolism , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/immunology , Behcet Syndrome/blood , Behcet Syndrome/immunology , Female , Humans , Immunosuppressive Agents/metabolism , Immunosuppressive Agents/therapeutic use , Leukocytes, Mononuclear/metabolism , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/immunology , Male , Middle Aged , Random Allocation , Severity of Illness Index , Statistics as Topic , Tumor Necrosis Factor Receptor Superfamily, Member 9
SELECTION OF CITATIONS
SEARCH DETAIL
...